[go: up one dir, main page]

MX2012008049A - Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. - Google Patents

Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.

Info

Publication number
MX2012008049A
MX2012008049A MX2012008049A MX2012008049A MX2012008049A MX 2012008049 A MX2012008049 A MX 2012008049A MX 2012008049 A MX2012008049 A MX 2012008049A MX 2012008049 A MX2012008049 A MX 2012008049A MX 2012008049 A MX2012008049 A MX 2012008049A
Authority
MX
Mexico
Prior art keywords
sub
compositions
methods
heterocyclic compounds
tricyclic heterocyclic
Prior art date
Application number
MX2012008049A
Other languages
English (en)
Inventor
Hazel Joan Dyke
Bohdan Waszkowycz
Sharada Shenvi Labadie
Joseph P Lyssikatos
Srinivasan Babu
Peter DRAGOVICH
Phillippe Bergeron
Paul Gibbons
Stefan Gradl
Emily Hanan
Michael Koehler
Rohan Mendonca
Rebacca Pulk
Mark Zak
Christopher Hurley
Tony Johnson
Janusz Josef Kulagowski
Stuart Ward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012008049A publication Critical patent/MX2012008049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona nuevos compuestos de la fórmula I que tienen la fórmula general: (Ver Formula) en la que R1, R2, R3, X e Y tienen los significados aquí descritos. Por consiguiente, los compuestos pueden incorporarse a composiciones farmacéuticamente aceptables y emplearse para el tratamiento de trastornos inmunológicos o hiperproliferativos.
MX2012008049A 2010-01-12 2011-01-11 Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. MX2012008049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29440410P 2010-01-12 2010-01-12
US36678510P 2010-07-22 2010-07-22
PCT/EP2011/050239 WO2011086053A1 (en) 2010-01-12 2011-01-11 Tricyclic heterocyclic compounds, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012008049A true MX2012008049A (es) 2012-08-01

Family

ID=43844551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008049A MX2012008049A (es) 2010-01-12 2011-01-11 Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.

Country Status (12)

Country Link
US (1) US8461328B2 (es)
EP (1) EP2523957A1 (es)
JP (1) JP2013517220A (es)
KR (1) KR20140015162A (es)
CN (1) CN102712640A (es)
AR (1) AR079984A1 (es)
BR (1) BR112012017269A2 (es)
CA (1) CA2781578A1 (es)
MX (1) MX2012008049A (es)
RU (1) RU2012132278A (es)
TW (1) TW201129565A (es)
WO (1) WO2011086053A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
AU2012295802B2 (en) * 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CA2888816A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
ES2755130T3 (es) 2013-02-08 2020-04-21 Nissan Chemical Corp Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
IN2013KO01293A (es) * 2013-11-13 2015-05-15 Univ Calcutta
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
ES2744213T3 (es) 2014-05-14 2020-02-24 Nissan Chemical Corp Compuesto tricíclico e inhibidor de JAK
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
BR112018075086B1 (pt) * 2016-07-14 2024-02-27 Eli Lilly And Company Derivados de pirazolilaminobenzimidazol, seu uso, e composição farmacêutica
ES2922379T3 (es) * 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
SI3568396T1 (sl) 2017-01-11 2021-04-30 Leo Pharma A/S Novi derivati amino-imidazopiridina koz zaviralci Janus kinaze in njihova farmacevtska uporaba
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US10636418B2 (en) 2017-03-22 2020-04-28 Google Llc Proactive incorporation of unsolicited content into human-to-computer dialogs
CN107917968A (zh) * 2017-04-10 2018-04-17 泰州市产品质量监督检验中心 一种高效液相色谱法测定皮革中偶氮二甲酰胺含量的方法
NZ763299A (en) 2017-09-14 2025-09-26 Daiichi Sankyo Co Ltd Compound having cyclic structure
EA037347B1 (ru) * 2017-12-08 2021-03-16 Янссен Фармацевтика Нв Низкомолекулярные ингибиторы киназ семейства jak
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
MX2021004517A (es) * 2018-11-01 2021-11-04 Lynk Pharmaceuticals Co Ltd Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN112300180B (zh) * 2019-07-26 2022-04-29 珠海宇繁生物科技有限责任公司 一种irak4激酶抑制剂及其制备方法
CN110483514B (zh) 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN110724142B (zh) * 2019-10-29 2022-09-02 启元生物(杭州)有限公司 一种作为jak激酶抑制剂的酰胺或磺酰胺取代的肼衍生物
MX2022006333A (es) * 2019-11-27 2022-06-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto triheterociclico como inhibidor de jak y uso del mismo.
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN116925077A (zh) * 2020-09-08 2023-10-24 一又生物(上海)有限公司 吡啶并环类化合物及其制备方法、中间体、组合物和应用
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
BR112023004550A2 (pt) * 2020-10-08 2023-05-02 Unichem Lab Ltd Compostos tricíclicos substituídos
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CN114790208B (zh) * 2021-01-26 2024-06-07 珠海宇繁生物科技有限责任公司 一种irak4激酶抑制剂及其制备方法
WO2022182839A1 (en) * 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN117295739B (zh) * 2021-05-26 2025-03-28 正大天晴药业集团股份有限公司 三并杂环类化合物的结晶和盐及其应用
EP4438604A4 (en) * 2021-11-25 2025-12-10 E Nitiate Biopharmaceuticals Hangzhou Co Ltd NEW CRYSTALLINE FORM OF THE COMPOUND, ITS PREPARATION PROCESS AND ITS USE
JP7688449B2 (ja) * 2021-12-21 2025-06-04 イーヨウ バイオテック （シャンハイ） カンパニー リミテッド ピリジン縮合環系化合物とその製造方法、中間体、組成物及び使用
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
WO2023194840A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
WO2023194842A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2023194841A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in ulcerative colitis
CN115403581B (zh) * 2022-07-18 2023-03-28 英矽智能科技(上海)有限公司 作为irak4抑制剂的杂环化合物
WO2025102268A1 (en) * 2023-11-15 2025-05-22 Lynk Pharmaceuticals Co. Ltd. Solid state forms, pharmaceutical compositions, preparation methods and use thereof
WO2025167710A1 (zh) * 2024-02-08 2025-08-14 凌科药业(杭州)有限公司 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
WO2025195451A1 (en) * 2024-03-21 2025-09-25 Lynk Pharmaceuticals Co. Ltd. Pharmaceutical compositions, dosage forms, and methods of preparation and use thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5910426A (en) 1990-11-28 1999-06-08 Ludwig Institute For Cancer Research Protein tyrosine kinase
US5821069A (en) 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US5852184A (en) 1990-11-28 1998-12-22 Ludwig Institute For Cancer Research Protein tyrosine kinase
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5378848A (en) 1992-02-12 1995-01-03 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
MX9700535A (es) 1994-07-21 1997-04-30 Akzo Nobel Nv Formulaciones de peroxido de cetona ciclico.
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK0980244T3 (da) 1997-05-06 2003-09-29 Wyeth Corp Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2306155A1 (en) 1997-11-06 1999-05-20 Philip Frost Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CZ303875B6 (cs) 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
AU2001285401A1 (en) 2000-08-07 2002-02-18 Neurogen Corporation Heterocyclic compounds as ligands of the GABAa receptor
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CA2453664A1 (en) 2001-07-16 2003-01-30 Takayuki Kasai Process for preparation of amidine derivatives
JP4155081B2 (ja) 2003-04-02 2008-09-24 トヨタ自動車株式会社 垂直離着陸装置
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7775432B2 (en) * 2003-10-16 2010-08-17 Nokia Corporation Terminal, method and computer program product for interacting with a signaling tag
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
US7346203B2 (en) * 2003-11-19 2008-03-18 General Electric Company Methods and apparatus for processing image data to aid in detecting disease
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
WO2005105788A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7288908B2 (en) * 2005-07-05 2007-10-30 Trw Automotive U.S. Llc Switching arrangement
JP4579072B2 (ja) * 2005-07-13 2010-11-10 富士フイルム株式会社 固体撮像素子の駆動方法及び固体撮像装置
CN101223168A (zh) * 2005-07-14 2008-07-16 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
MX2008001334A (es) 2005-07-29 2008-03-24 Pfizer Prod Inc Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis.
US20090240055A1 (en) 2005-09-23 2009-09-24 Krepski Larry R Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof
US7702341B2 (en) * 2005-10-03 2010-04-20 Yahoo! Inc. Shortcut for establishing a communication channel with a remote device over a network
EP1772692A1 (de) * 2005-10-05 2007-04-11 Oschatz Gmbh Vorrichtung zur Abkühlung von Abgasen
US7681109B2 (en) * 2005-10-13 2010-03-16 Ramot At Tel Aviv University Ltd. Method of error correction in MBC flash memory
WO2007075468A1 (en) 2005-12-16 2007-07-05 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7767061B2 (en) * 2006-08-02 2010-08-03 Wausau Paper Towel & Tissue, Llc Wet/dry crepe swing paper machinery
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
US7648338B1 (en) * 2006-09-14 2010-01-19 Sikorsky Aircraft Corporation Dual higher harmonic control (HHC) for a counter-rotating, coaxial rotor system
US7652053B2 (en) 2006-11-30 2010-01-26 Hoffmann-La Roche Inc. Diaminocycloalkane MCH receptor antagonists
JP5287253B2 (ja) 2007-01-12 2013-09-11 アステラス製薬株式会社 縮合ピリジン化合物
CA2690832C (en) * 2007-06-15 2014-05-06 Gear & Broach, Incorporated Vehicular actuator arrangement and implementations
US20090111337A1 (en) * 2007-10-26 2009-04-30 Bridgeport Fittings, Inc. Electrical connector
US20090137945A1 (en) 2007-11-28 2009-05-28 Claire Marquez Electro Collagen Induction Therapy Device
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
HUE028347T2 (en) 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
EP2356120B1 (en) 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
US20100311714A1 (en) 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
US20110012540A1 (en) * 2009-07-17 2011-01-20 Superiorlite Corporation Limited Multipurpose flame light
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
HUE033099T2 (en) 2009-12-01 2017-11-28 Abbvie Inc Novel tricyclic compounds

Also Published As

Publication number Publication date
RU2012132278A (ru) 2014-02-20
EP2523957A1 (en) 2012-11-21
KR20140015162A (ko) 2014-02-06
CA2781578A1 (en) 2011-07-21
US20110201593A1 (en) 2011-08-18
US8461328B2 (en) 2013-06-11
AR079984A1 (es) 2012-03-07
WO2011086053A1 (en) 2011-07-21
TW201129565A (en) 2011-09-01
BR112012017269A2 (pt) 2016-05-03
CN102712640A (zh) 2012-10-03
JP2013517220A (ja) 2013-05-16

Similar Documents

Publication Publication Date Title
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
CA2818187C (en) Bromodomain inhibitors and uses thereof
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
MX2013011054A (es) Antagonistas de trpvi.
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY153915A (en) Organic compounds
PH12014501469A1 (en) Bromodomain inhibitors
MX2013004491A (es) Boronatos como inhibidores de arginasa.
CA2871471C (en) Dna-pk inhibitors
IN2012DN01233A (es)
EA201490357A1 (ru) Индазолы
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2010003612A (es) Derivados de oxadiazol.
EA201171210A1 (ru) Производные оксадиазола
MX340714B (es) Inhibidores de hsp90.
MX2010007392A (es) Antagonistas de trpa1.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MX2010007391A (es) Antagonistas de trpa1.
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof